Bayer elects Werner Wenning as chairman

Monday, September 17, 2012 03:08 PM

Bayer’s  supervisory board has elected Werner Wenning as its chairman, who had already been elected by the Annual Stockholders' Meeting of Bayer in April 27, 2012, to become a member of the supervisory board effective October 1.

Wenning served as chairman of the board of management of Bayer from April 2002 until September 2010. The statutory “cooling-off period,” after which a former member of a company’s board of management may join its supervisory board, ends after two years.

Wenning's career with Bayer spanned nearly 45 years, during which he rose from trainee to CEO. Wenning joined the company in 1966 as a commercial trainee, and subsequently held a number of positions with Bayer in Germany and abroad before being appointed to the board of management as CFO in February 1997. Five years later—in April 2002—he became chairman of the board of management of the pharmaceuticals and chemicals group.

Milestones during Wenning’s tenure as CEO included the strategic realignment of the Bayer Group and the spin-off of the traditional chemicals business under the name Lanxess. The most important and strategically decisive step toward expanding the life science business was the acquisition of Schering, of Berlin, Germany, in 2006.

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs